Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $11.22 billion. The enterprise value is $11.49 billion.
| Market Cap | 11.22B |
| Enterprise Value | 11.49B |
Important Dates
The next confirmed earnings date is Wednesday, October 30, 2024, before market open.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | Aug 19, 2024 |
Share Statistics
Bio-Techne has 158.67 million shares outstanding. The number of shares has decreased by -0.67% in one year.
| Shares Outstanding | 158.67M |
| Shares Change (YoY) | -0.67% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 1.05% |
| Owned by Institutions (%) | 98.74% |
| Float | 156.88M |
Valuation Ratios
The trailing PE ratio is 67.37 and the forward PE ratio is 37.89. Bio-Techne's PEG ratio is 3.37.
| PE Ratio | 67.37 |
| Forward PE | 37.89 |
| PS Ratio | 9.63 |
| Forward PS | 8.90 |
| PB Ratio | 5.41 |
| P/FCF Ratio | 47.54 |
| PEG Ratio | 3.37 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 37.02, with an EV/FCF ratio of 48.67.
| EV / Earnings | 68.37 |
| EV / Sales | 9.91 |
| EV / EBITDA | 37.02 |
| EV / EBIT | 46.85 |
| EV / FCF | 48.67 |
Financial Position
The company has a current ratio of 3.87, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.87 |
| Quick Ratio | 2.47 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 1.26 |
| Debt / FCF | 1.78 |
| Interest Coverage | 15.59 |
Financial Efficiency
Return on equity (ROE) is 8.33% and return on invested capital (ROIC) is 6.24%.
| Return on Equity (ROE) | 8.33% |
| Return on Assets (ROA) | 5.74% |
| Return on Capital (ROIC) | 6.24% |
| Revenue Per Employee | $380,020 |
| Profits Per Employee | $55,106 |
| Employee Count | 3,050 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, Bio-Techne has paid $17.58 million in taxes.
| Income Tax | 17.58M |
| Effective Tax Rate | 9.47% |
Stock Price Statistics
The stock price has increased by +18.81% in the last 52 weeks. The beta is 1.27, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | +18.81% |
| 50-Day Moving Average | 73.54 |
| 200-Day Moving Average | 73.38 |
| Relative Strength Index (RSI) | 43.82 |
| Average Volume (20 Days) | 814,277 |
Short Selling Information
The latest short interest is 3.60 million, so 2.27% of the outstanding shares have been sold short.
| Short Interest | 3.60M |
| Short Previous Month | 3.52M |
| Short % of Shares Out | 2.27% |
| Short % of Float | 2.30% |
| Short Ratio (days to cover) | 4.47 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.16 billion and earned $168.07 million in profits. Earnings per share was $1.05.
| Revenue | 1.16B |
| Gross Profit | 770.45M |
| Operating Income | 245.26M |
| Pretax Income | 232.35M |
| Net Income | 168.07M |
| EBITDA | 310.37M |
| EBIT | 245.26M |
| Earnings Per Share (EPS) | $1.05 |
Balance Sheet
The company has $152.86 million in cash and $419.54 million in debt, giving a net cash position of -$266.68 million or -$1.68 per share.
| Cash & Cash Equivalents | 152.86M |
| Total Debt | 419.54M |
| Net Cash | -266.68M |
| Net Cash Per Share | -$1.68 |
| Equity (Book Value) | 2.07B |
| Book Value Per Share | 13.08 |
| Working Capital | 458.04M |
Cash Flow
In the last 12 months, operating cash flow was $298.98 million and capital expenditures -$62.88 million, giving a free cash flow of $236.10 million.
| Operating Cash Flow | 298.98M |
| Capital Expenditures | -62.88M |
| Free Cash Flow | 236.10M |
| FCF Per Share | $1.49 |
Margins
Gross margin is 66.47%, with operating and profit margins of 21.16% and 14.50%.
| Gross Margin | 66.47% |
| Operating Margin | 21.16% |
| Pretax Margin | 16.02% |
| Profit Margin | 14.50% |
| EBITDA Margin | 26.78% |
| EBIT Margin | 21.16% |
| FCF Margin | 21.76% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.45%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.45% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 30.48% |
| Buyback Yield | 0.67% |
| Shareholder Yield | 1.12% |
| Earnings Yield | 1.50% |
| FCF Yield | 2.10% |
Analyst Forecast
The average price target for Bio-Techne is $80.67, which is 14.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $80.67 |
| Price Target Difference | 14.04% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 11.34% |
| EPS Growth Forecast (5Y) | 31.73% |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 12.42 and a Piotroski F-Score of 5.
| Altman Z-Score | 12.42 |
| Piotroski F-Score | 5 |